S&P 500   3,226.31 (-0.33%)
DOW   26,670.50 (-0.35%)
QQQ   265.43 (+0.48%)
AAPL   108.55 (+1.33%)
MSFT   203.11 (+1.26%)
FB   249.37 (+0.14%)
GOOGL   1,427.78 (+1.30%)
AMZN   3,034.06 (+1.14%)
NVDA   495.10 (+2.09%)
TSLA   373.63 (-1.77%)
BABA   269.14 (-1.40%)
CGC   14.35 (-1.71%)
GE   6.06 (-0.82%)
MU   49.49 (-0.72%)
AMD   76.48 (+2.34%)
T   27.99 (+0.43%)
F   6.58 (-0.90%)
ACB   5.21 (+0.77%)
GILD   62.62 (-0.74%)
NFLX   472.81 (+0.47%)
DIS   123.25 (-0.02%)
BAC   23.43 (+0.73%)
BA   147.17 (-2.65%)
S&P 500   3,226.31 (-0.33%)
DOW   26,670.50 (-0.35%)
QQQ   265.43 (+0.48%)
AAPL   108.55 (+1.33%)
MSFT   203.11 (+1.26%)
FB   249.37 (+0.14%)
GOOGL   1,427.78 (+1.30%)
AMZN   3,034.06 (+1.14%)
NVDA   495.10 (+2.09%)
TSLA   373.63 (-1.77%)
BABA   269.14 (-1.40%)
CGC   14.35 (-1.71%)
GE   6.06 (-0.82%)
MU   49.49 (-0.72%)
AMD   76.48 (+2.34%)
T   27.99 (+0.43%)
F   6.58 (-0.90%)
ACB   5.21 (+0.77%)
GILD   62.62 (-0.74%)
NFLX   472.81 (+0.47%)
DIS   123.25 (-0.02%)
BAC   23.43 (+0.73%)
BA   147.17 (-2.65%)
S&P 500   3,226.31 (-0.33%)
DOW   26,670.50 (-0.35%)
QQQ   265.43 (+0.48%)
AAPL   108.55 (+1.33%)
MSFT   203.11 (+1.26%)
FB   249.37 (+0.14%)
GOOGL   1,427.78 (+1.30%)
AMZN   3,034.06 (+1.14%)
NVDA   495.10 (+2.09%)
TSLA   373.63 (-1.77%)
BABA   269.14 (-1.40%)
CGC   14.35 (-1.71%)
GE   6.06 (-0.82%)
MU   49.49 (-0.72%)
AMD   76.48 (+2.34%)
T   27.99 (+0.43%)
F   6.58 (-0.90%)
ACB   5.21 (+0.77%)
GILD   62.62 (-0.74%)
NFLX   472.81 (+0.47%)
DIS   123.25 (-0.02%)
BAC   23.43 (+0.73%)
BA   147.17 (-2.65%)
S&P 500   3,226.31 (-0.33%)
DOW   26,670.50 (-0.35%)
QQQ   265.43 (+0.48%)
AAPL   108.55 (+1.33%)
MSFT   203.11 (+1.26%)
FB   249.37 (+0.14%)
GOOGL   1,427.78 (+1.30%)
AMZN   3,034.06 (+1.14%)
NVDA   495.10 (+2.09%)
TSLA   373.63 (-1.77%)
BABA   269.14 (-1.40%)
CGC   14.35 (-1.71%)
GE   6.06 (-0.82%)
MU   49.49 (-0.72%)
AMD   76.48 (+2.34%)
T   27.99 (+0.43%)
F   6.58 (-0.90%)
ACB   5.21 (+0.77%)
GILD   62.62 (-0.74%)
NFLX   472.81 (+0.47%)
DIS   123.25 (-0.02%)
BAC   23.43 (+0.73%)
BA   147.17 (-2.65%)
Log in
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$86.00
-1.14 (-1.31 %)
(As of 09/24/2020 10:28 AM ET)
Add
Compare
Today's Range
$85.73
Now: $86.00
$87.29
50-Day Range
$88.60
MA: $92.81
$96.35
52-Week Range
$62.55
Now: $86.00
$101.28
Volume93,927 shs
Average Volume7.28 million shs
Market Capitalization$151.78 billion
P/E Ratio18.30
Dividend Yield5.33%
Beta0.75
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.18 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.04 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,764,830,000
Market Cap$151.78 billion
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$86.00
-1.14 (-1.31 %)
(As of 09/24/2020 10:28 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock price been impacted by Coronavirus (COVID-19)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 1.6% and is now trading at $86.22.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AbbVie?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AbbVie
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) posted its earnings results on Friday, July, 31st. The company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.20 by $0.14. The company earned $10.43 billion during the quarter, compared to the consensus estimate of $10.14 billion. AbbVie had a net margin of 19.20% and a negative return on equity of 628.57%. AbbVie's revenue was up 26.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.26 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, September 11th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.18 per share on Monday, November 16th. This represents a $4.72 annualized dividend and a yield of 5.47%. The ex-dividend date is Wednesday, October 14th.
View AbbVie's dividend history
.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has initiated a share buyback program on Thursday, December 13th 2018, which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 3.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's board believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share guidance of $10.35-10.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.51.

What price target have analysts set for ABBV?

16 equities research analysts have issued 1 year target prices for AbbVie's stock. Their forecasts range from $90.00 to $127.00. On average, they anticipate AbbVie's stock price to reach $108.33 in the next year. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for AbbVie
.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.35%), BlackRock Inc. (6.99%), FMR LLC (1.78%), Nuveen Asset Management LLC (1.25%), Bank of New York Mellon Corp (1.21%) and Charles Schwab Investment Management Inc. (0.48%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, LSV Asset Management, Advisor Group Holdings Inc., Federated Hermes Inc., Toronto Dominion Bank, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., and Russell Investments Group Ltd.. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
.

Which major investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Nuveen Asset Management LLC, Nordea Investment Management AB, Bank of New York Mellon Corp, AQR Capital Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $86.22.

How big of a company is AbbVie?

AbbVie has a market capitalization of $152.16 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.